Navigation Links
Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
Date:2/25/2009

Angiomax Will Remain the NSTEMI Market Share Leader Through 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on incidence of mortality at 30 days is the attribute that most influences surveyed cardiologists' prescribing decisions in non-ST elevation myocardial infarction (NSTEMI). Data and the opinions of interviewed thought leaders indicate that current and emerging drugs, including Eli Lilly/Daiichi Sankyo's Efient, have no advantage in this attribute over The Medicines Company's Angiomax, the market sales leading agent.

The new report entitled NSTEMI: Finding the Balance between Efficacy and Safety finds that a drug that reduces mortality more than Angiomax at 30 days with significantly lower rates of bleeding would earn a 50 percent patient share in the United States and a 60 percent patient share in Europe, according to surveyed U.S. and European cardiologists. Angiomax, which was Decision Resources' proprietary clinical gold standard in 2008 for NSTEMI, will remain the clinical gold standard therapy and the market share leader through 2017, due to its efficacy and safety

The report finds that although some therapies in development for NSTEMI hold promise, most have either efficacy or safety and tolerability features that surveyed cardiologists rated inferior when compared with Angiomax. New agents in the market include Efient, which was approved by the European Medicines Agency in February 2009 for treatment of NSTEMI in the European Union.

"Angiomax has the most robust clinical data of drugs in its class for its use in NSTEMI and benefits from an immediate onset of action, which has driven physician usage and has enabled it to dominate the NSTEMI market," said Decision Resources Analyst
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
2. Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand
3. Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
4. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
5. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
6. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
7. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
8. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
9. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
10. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
11. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... LONDON , October 31, 2014 ... (NYSE: MDT ), Abbott Laboratories (NYSE: ... Inc. (NYSE: RMD ), and Covidien PLC (NYSE: ... at: http://investor-edge.com/register . The US markets on ... the Dow Jones Industrial Average finished at 17,195.42, up 1.30% ...
(Date:10/31/2014)... Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, ... 30, 2014. Brian M. Culley, the ... productive for Mast. Consistent with prior guidance, our 388-patient pivotal ... is on track to complete enrollment by the end ... in the U.S. and more than ten study sites ...
(Date:10/31/2014)... , October 31, 2014 ... a clinical-stage pharmaceutical company focused on the development ... company will host a conference call to discuss ... trial of ORMD-0801, the company,s proprietary oral insulin ... November 3, 2014 at 10:00 a.m. Eastern time. ...
Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
... 15, 2011 MIM Software Inc., a leading global ... MIM™ is available on the U.S. App Store. This ... the app had received 510(k) clearance for remote diagnostic ... the iPhone®, iPod touch®, and iPad®. (Photo: ...
... Fla., Feb. 15, 2011 The Florida Society of ... of Pain Medicine ( www.fapmmed.net ) and The American ... President Mike Haridopolos and Attorney General Pam Bondi for ... and their opposition to the recently announced attempt to ...
Cached Medicine Technology:Mobile MIM, First FDA-Cleared Diagnostic Medical Imaging App, Now Available on the U.S. App Store 2Mobile MIM, First FDA-Cleared Diagnostic Medical Imaging App, Now Available on the U.S. App Store 3Florida Pain Clinic Organizations Applaud FL Senate President Haridopolos and Attorney General Bondi 2
(Date:10/31/2014)... effort by the National Institutes of Health will ... to reframe mental health research, from diagnosis to ... recently established by the National Institute of Mental ... development of the institute,s RDoC initiative. , ... accelerate the pace of research that translates basic ...
(Date:10/31/2014)... News) -- A comparison of two of the most ... gastric bypass helped patients shed more excess pounds than ... short-term complications and long-term hospitalizations. Gastric-bypass surgery makes ... your body does not absorb all the calories from ... Health. Gastric banding is a type of weight-loss procedure ...
(Date:10/31/2014)... Steven Reinberg HealthDay Reporter THURSDAY, ... increase slightly the risk of broken bones and injured joints, a ... found that among 7 percent of people who had an eczema ... joint injury and 0.6 percent had an injury that caused a ... with the skin condition had more than double the risk of ...
(Date:10/30/2014)... one day provide new treatments for injuries and damage ... , Cartilage, for example, is a hard material that ... work smoothly. UC Davis biomedical engineers, exploring ways to ... outside the body, report new developments this week in ... Sciences . , "The problem with engineered tissue is ...
(Date:10/30/2014)... , A mathematical model developed by NIH grantees predicts ... to prevent HIV infection via vaginal sex, whereas just ... infection via anal sex. This finding helps explain why ... PrEP, in women failed to show efficacy. Participants in ... of Truvada and tenofovir (another antiretroviral) for HIV prevention ...
Breaking Medicine News(10 mins):Health News:NIMH creates new unit to support its research domain criteria initiative 2Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2
... that occurs when a joint is damaged by injury or ... it comes to the knee, that inflammation can actually interfere ... may lead to treatments for injuries or osteoarthritis in the ... are drugs that can block the action of these immune ...
... with patients reduced risk by 10% and also cut ... management provided a cost-effective way of reducing patients, overall ... to a study by researchers at Stanford University in ... professionals such as nurses and dietitians help patients manage ...
... thirds (69%) of sexually active New York City teens use ... of public high school students. But too few sexually active ... prevent unplanned pregnancies. The full report Teen Sexual Activity ... available at www.nyc.gov/html/doh/downloads/pdf/survey/survey-2007youthsex.pdf . It finds that in New ...
... postpartum depression, study suggests , , WEDNESDAY, Aug. 29 (HealthDay News) ... mother be as simple as seeing which arm she uses ... that mothers who cradle their baby on their right side ... new mothers feel some levels of stress during the first ...
... (RA), an autoimmune disease marked by chronic inflammation of ... incidence of cancer is complicated. Epidemiologic studies have ... increased among RA patients, while breast and colon cancers ... by the nature of RA or by immunosuppressive drugs ...
... study confirms , , TUESDAY, Aug. 28 (HealthDay News) -- ... go together, a new study finds that it is ... more alcohol problems a man has, the more likely ... a disadvantaged neighborhood," according to a team of University ...
Cached Medicine News:Health News:New insights into common knee injuries 2Health News:Case Management Cost-Effective Way to Cut Heart Risks 2Health News:More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag 2Health News:More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag 3Health News:Stressed-Out Moms Carry Babies on the Right 2Health News:Biologic treatment for rheumatoid arthritis and the risk of cancer 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 2Health News:Drinking Often Spurs Move to Poorer Neighborhoods 3
... and conveniently controls the temperature at your lab ... levels up to 99 C*, with the "plus" ... as 5 C. The thermoblocks for 0.2 ml**, ... microplates enable a high degree of flexibility for ...
... 10k units Pen.,10k ug Strept. ... Cell Culture Reagent and Buffer ... with cGMP regulations and are ... compatibility. , Typical Properties, Sterility ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
... A combination of penicillin and ... gram positive and gram negative bacteria ... of 100,000 I.U. Penicillin/100,000 g/mL Streptomycin ... prepared in water at concentrations of ...
Medicine Products: